Characterization of a Novel Pathogenic <scp><i>PLCG2</i></scp> Variant Leading to APLAID Syndrome Responsive to a TNF Inhibitor
Zhaohui Yang(Second Affiliated Hospital of Zhejiang University), Xiaomin Yu(First Affiliated Hospital Zhejiang University)
Cited by 3
Related Papers
Modulation of p53, ErbB1, ErbB2, and Raf-1 Expression in Lung Cancer Cells by Depsipeptide FR901228
|JNCI Journal of the National Cancer Institute|2002|359
A dominant pathogenic MEFV mutation causes atypical pyrin-associated periodic syndromes
|JCI Insight|2023|12
Novel USP18 mutations lead to severe interferonopathy responsive to JAK inhibitor
|Frontiers in Immunology|2025|1